Abstract
The treatment of gout is based on several principles. Symptom control and termination of the inflammatory process are important early goals, whereas the urate level should be lowered in the long term to prevent further gout attacks and complications. The non-pharmacological approach is based on individually informing the patient on dietary measures and changes of life style. Besides physical measures, such as cold applications on the affected joint, various medications are available for treatment of an acute gout attack. The choice of drug depends on the individual risk profile. If non-steroidal anti-inflammatory drugs (NSAID) and coxibs are chosen it should be taken into account that the use is restricted in patients with renal insufficiency. Moreover, these drugs may have gastrointestinal side effects and are associated with increased cardiovascular morbidity and mortality. Colchicine has gastrointestinal side effects at high dosages but can also be used for differential diagnostics if there is a quick response to treatment. Steroids are an effective alternative and can be given orally or parenterally in patients with dysphagia. Moreover, steroids can be used in cases of renal insufficiency. After symptoms of the acute attack have subsided, urate lowering therapy should be initiated to prevent further attacks. Low-dose urate lowering therapy can be started during an acute gout attack when acute therapy is initiated. Allopurinol is still the medication of choice but its use is restricted in patients with renal insufficiency. A rare but serious side effect is allopurinol hypersensitivity syndrome. Febuxostat can be an alternative in patients who do not tolerate allopurinol. In February 2016, lesinurad, an URAT-1 and OAT-4 inhibitor, was approved in combination with allopurinol or febuxostat. Data on the effectiveness and safety of synthetic uricases and biologicals are still sparse for elderly patients. These substances are reserved for severe cases of gout.
Zusammenfassung
Die Therapie der Gicht beim älteren Menschen basiert auf mehreren Prinzipien. Während beim akuten Gichtanfall die Erreichung einer schnellen Beschwerdefreiheit durch Beendigung der akuten Inflammation im Vordergrund steht, zielt die dauerhafte Senkung der Harnsäure auf eine Vermeidung weiterer Anfälle und Vermeidung von Komplikationen hin. Die individuelle Information des Patienten hinsichtlich diätischer Maßnahmen und einer Umstellung der Lebensweise stellt die Basis der nichtpharmakologischen Therapie dar. Zur Unterbrechung des akuten Gichtanfalls stehen neben physikalischen Maßnahmen wie der Kühlung des betroffenen Gelenks verschiedenste Medikamente zur Verfügung. Die Auswahl ist abhängig vom individuellen Risikoprofil. Beim Einsatz von NSAR und Coxiben müssen die Nierenfunktion und das Auftreten von gastrointestinalen Schleimhautschäden wie auch die erhöhte kardiovaskuläre Morbidität/Mortalität bedacht werden. Colchizin hat in höherer Dosierung zahlreiche gastrointestinale Nebenwirkungen, kann aber bei Ansprechen der Therapie auch zur Differenzialdiagnose genutzt werden. Glukokortikoide können oral oder bei Schluckstörung i. v. eine Alternative darstellen und bei bestehender Niereninsuffizienz eingesetzt werden. Unter Therapie eines akuten Gichtanfalls kann bereits eine niedrig dosierte harnsäuresenkende Therapie eingeleitet werden. Allopurinol hat sich in der Praxis bewährt, Limitationen bestehen bei Niereninsuffizienz. Das Allopurinol-Hypersensitivitätssyndrom stellt eine seltene schwerwiegende Nebenwirkung dar. Febuxostat kann bei Unverträglichkeit von Allopurinol eine Alternative sein. Im Februar 2016 wurde Lesinurad, ein URAT-1- und OAT-4-Inhibitor, in Kombination mit Allopurinol oder Febuxostat zugelassen. Für die Therapie mit synthetischen Urikasen oder Biologikals existieren für geriatrische Patienten noch wenige Daten. Diese bleiben schweren Verläufen vorbehalten.
Similar content being viewed by others
References
Ahern MJ, Reid C, Gordon TP et al (1987) Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17:301–304
Antman EM, Bennett JS, Daugherty A et al (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: A scientific statement from the american heart association. Circulation 115:1634–1642
Bauer J, Biolo G, Cederholm T et al (2013) Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 14:542–559
Becker MSHJ, Espinoza L, Wells A, Macdonald P, Lloyd E, Lademacher C (2008) A phase 3 randomized, controlled, multicenter, double-blind trial comparing effiancy and safety of daily febuxostat and allopurinol in subjects with gout. Meeting of the American College of Rheumatology, San Francisco, California.
Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63
Becker MA, Schumacher HR Jr., Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461
Becker MA, Schumacher HR Jr., Wortmann RL et al (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52:916–923
Choi HK, Atkinson K, Karlson EW et al (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med 165:742–748
Choi HK, Atkinson K, Karlson EW et al (2004) Alcohol intake and risk of incident gout in men: A prospective study. Lancet 363:1277–1281
Choi HK, Curhan G (2008) Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336:309–312
Choi HK, Willett W, Curhan G (2010) Fructose-rich beverages and risk of gout in women. JAMA 304:2270–2278
Cipriani S, Chen X, Schwarzschild MA (2010) Urate: A novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med 4:701–712
Clegg A, Young JB (2011) Which medications to avoid in people at risk of delirium: A systematic review. Age Ageing 40:23–29
Dessein PH, Shipton EA, Stanwix AE et al (2000) Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: A pilot study. Ann Rheum Dis 59:539–543
Evans TI, Wheeler MT, Small RE et al (1996) A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol 23:143–148
Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: Evidence supporting it. Ann Neurol 32:804–812
Fernandez C, Noguera R, Gonzalez JA et al (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26:2285–2286
Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47–56
Hernan MA, Chen H, Schwarzschild MA et al (2003) Alcohol consumption and the incidence of Parkinson’s disease. Ann Neurol 54:170–175
Hoskison KT, Wortmann RL (2007) Management of gout in older adults: Barriers to optimal control. Drugs Aging 24:21–36
Kaneko K, Aoyagi Y, Fukuuchi T et al (2014) Total purine and purine base content of common foodstuffs for facilitating nutritional therapy for gout and hyperuricemia. Biol Pharm Bull 37:709–721
Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431–1446
Khanna D, Khanna PP, Fitzgerald JD et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447–1461
Kingsbury SR, Conaghan PG, Mcdermott MF (2011) The role of the NLRP3 inflammasome in gout. J Inflamm Res 4:39–49
Macdonald TM, Ford I, Nuki G et al (2014) Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open 4:e005354
Muller-Ladner U, Panzner I, Kriegsmann J et al (2011) Gout – regardless of therapeutic options a “forgotten” disease. Dtsch Med Wochenschr 136:1660–1664
Neogi T (2011) Clinical practice. Gout. N Engl J Med 364:443–452
Palacios N, Gao X, O’reilly E et al (2012) Alcohol and risk of Parkinson’s disease in a large, prospective cohort of men and women. Mov Disord 27:980–987
Reinders MK, Jansen TL (2010) Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging 5:7–18
Richette P, Doherty M, Pascual E et al (2016) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 0:1–14
Schlesinger N, Detry MA, Holland BK et al (2002) Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 29:331–334
Schumacher HR Jr., Boice JA, Daikh DI et al (2002) Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 324:1488–1492
Sivera F, Andres M, Carmona L et al (2014) Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 73:328–335
Stamp LK, Jordan S (2011) The challenges of gout management in the elderly. Drugs Aging 28:591–603
Stamp LK, O’donnell JL, Zhang M et al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:412–421
Tausche AK, Aringer M, Schroeder HE et al (2008) The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med 121:e3–e4
Wallace SL, Singer JZ (1988) Review: Systemic toxicity associated with the intravenous administration of colchicine – guidelines for use. J Rheumatol 15:495–499
Yeomans ND (2015) Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs? BMC Med 13:56
Zhang W, Doherty M, Pascual E et al (2011) EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Ann Rheum Dis 70:571–575
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
S. Schlee,C. Bollheimer, T. Bertsch, C.C. Sieber and P. Härle declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Schlee, S., Bollheimer, L.C., Bertsch, T. et al. Crystal arthritides – gout and calcium pyrophosphate arthritis. Z Gerontol Geriat 51, 703–710 (2018). https://doi.org/10.1007/s00391-017-1199-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00391-017-1199-1